Balanced Fluids for Pediatric Sepsis
(PRoMPT BOLUS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on fluid resuscitation for septic shock in children.
Is it safe to use balanced fluids like Lactated Ringer's or Plasma-Lyte in humans?
How is the treatment with balanced fluids different for pediatric sepsis?
What data supports the effectiveness of the treatment Lactated Ringer's and similar solutions for pediatric sepsis?
Research suggests that using balanced fluids like Lactated Ringer's or Plasma-Lyte instead of normal saline may improve outcomes for sepsis patients, as they are associated with fewer complications like kidney injury and metabolic acidosis (a condition where the body produces too much acid). These balanced solutions may lead to better recovery in children with sepsis.46789
Who Is on the Research Team?
Fran Balamuth, MD PhD MSCE
Principal Investigator
Attending Physician, Emergency Department
Are You a Good Fit for This Trial?
This trial is for children aged over 2 months and under 18 years with a physician's diagnosis of septic shock needing antibiotics and fluid resuscitation. It excludes those with certain metabolic disorders, known pregnancy, prisoners, allergies to crystalloid fluids, severe liver or kidney issues, high potassium or calcium levels, or if the clinician deems it unsafe.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either balanced fluids (BF) or 0.9% normal saline (NS) for fluid resuscitation immediately after randomization through the next calendar day
Follow-up
Participants are monitored for safety and effectiveness after treatment, with primary endpoint being major adverse kidney events within 30 days
Extended Follow-up
Participants are monitored for additional outcomes such as all-cause mortality at 90 days
What Are the Treatments Tested in This Trial?
Interventions
- Lactated Ringer
- Normal Saline
- Plasma-lyte
Lactated Ringer is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital of Philadelphia
Lead Sponsor
Queensland Children's Hospital
Collaborator
Queen's University
Collaborator
Kingston Health Sciences Centre
Collaborator
Townsville University Hospital
Collaborator
Queensland Children's Hospital
Collaborator
Royal Children's Hospital
Collaborator
The Children's Hospital of Winnipeg
Collaborator
Westmead Children's Hospital
Collaborator
Children's Hospital and Health System Foundation, Wisconsin
Collaborator